Navigation Links
Mast Therapeutics To Present At Cowen And Company's 35th Annual Healthcare Conference On March 2nd
Date:2/24/2015

SAN DIEGO, Feb. 24, 2015 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at Cowen and Company's 35th Annual Healthcare Conference on Monday, March 2, 2015 at 4:50 p.m. Eastern time in Salon H at the Boston Marriott Copley Place hotel in Boston.

Interested parties can access a live audio webcast on the Mast Therapeutics web site at www.masttherapeutics.com. An archived presentation will be available on the web site for 30 days.

About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California.  The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop vepoloxamer (MST-188), its lead product candidate, for serious or life-threatening diseases and conditions typically characterized by impaired microvascular blood flow and damaged cell membranes. 

The Company is enrolling subjects in EPIC, a pivotal Phase 3 study of vepoloxamer in sickle cell disease, and in a Phase 2 study to evaluate whether vepoloxamer improves the effectiveness of recombinant tissue plasminogen activator therapy in patients with acute limb ischemia.  The Company also is planning to initiate a Phase 2 study of vepoloxamer in patients with heart failure this year. More information can be found on the Company's web site at www.masttherapeutics.com. (Twitter: @MastThera

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking Statements
Mast Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to anticipated timing of development milestones for the company's product candidates, including commencement of a Phase 2 study of vepoloxamer in heart failure. Among the factors that could cause or contribute to material differences between the Company's actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the uncertainty of outcomes in ongoing and future studies of the Company's product candidates and the risk that its product candidates, including vepoloxamer, may not demonstrate adequate safety, efficacy or tolerability in one or more such studies; delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing sufficient quantities of clinical trial material, being subject to a "clinical hold," and/or suspension or termination of a clinical study, including due to patient safety concerns or lack of funding; the potential for additional nonclinical or clinical studies to be required prior to initiation of a planned clinical study; the risk that, even if clinical studies are successful, the FDA or other regulatory agencies may determine they are not sufficient to support a new drug application; the potential that, even if clinical studies of a product candidate in one indication are successful, clinical studies in another indication may not be successful; the Company's reliance on contract research organizations (CROs), contract manufacturing organizations (CMOs), and other third parties to assist in the conduct of important aspects of development of its product candidates, including clinical studies, manufacturing, and regulatory activities for its product candidates, and that such third parties may fail to perform as expected; the Company's ability to obtain additional funding on a timely basis or on acceptable terms, or at all; the potential for the Company to delay, reduce or discontinue current and/or planned development activities, including clinical studies, partner its product candidates at inopportune times or pursue less expensive but higher-risk and/or lower return development paths if it is unable to raise sufficient additional capital as needed; the risk that, even if the Company successfully develops a product candidate in one or more indications, it may not realize commercial success and may never achieve profitability; the risk that the Company is not able to adequately protect its intellectual property rights and prevent competitors from duplicating or developing equivalent versions of its product candidates; and other risks and uncertainties more fully described in the Company's press releases and periodic filings with the Securities and Exchange Commission. The Company's public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Mast Therapeutics does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law.

Logo - http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a

 


'/>"/>
SOURCE Mast Therapeutics, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. United Therapeutics Corporation Reports 2014 Fourth Quarter And Annual Financial Results
2. Orexigen Therapeutics to Speak at the 2015 RBC Capital Markets Global Healthcare Conference
3. Oxford BioTherapeutics to Present at 35th Cowen and Company Annual Health Care Conference in Boston
4. Orexigen Therapeutics to Host Full Year and Fourth Quarter 2014 Financial Results Conference Call and Webcast
5. Edison Initiates Coverage on Relmada Therapeutics
6. Global Pain Therapeutics Drugs, Markets and Companies Report 2015 - Forecasts to 2024
7. Transition Therapeutics Inc. Announces Pricing of Public Offering of US$20 Million of Common Shares
8. Immunomic Therapeutics, Inc. Appoints Vice President of Operations
9. Transition Therapeutics Announces Second Quarter Fiscal 2015 Financial Results
10. PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11. United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2019)... ... October 07, 2019 , ... Erchonia Corporation, the global ... today announces that the U.S. Food and Drug Administration (FDA) has granted the ... temporary relief of chronic neck and shoulder pain of musculoskeletal origin. , Erchonia ...
(Date:10/3/2019)... ... , ... Murrieta Genomics , the launch pad for genomic sequencing startups, ... Valley at a special Life Science showcase event on October 10th, 2019 ... Lake Business Center located at 340 E. Middlefield Road in Mountain View, California. ...
(Date:9/24/2019)... ... September 24, 2019 , ... ... of high-level X-ray methods using synchrotron-produced X-rays to study amorphous drug formulations. ... present “Synchrotron X-Ray Diffraction and Pair Distribution Function Analysis of Drug/Polymer Dispersions: ...
(Date:9/24/2019)... , ... September 24, 2019 , ... In the past ... research led by faculty at South Dakota School of Mines & Technology ... microbes that attach to surfaces to form a slimy and yet strong layer which ...
Breaking Biology Technology:
(Date:10/3/2019)... ... October 01, 2019 , ... The ... of chemicals, reagents, and medias and to be a more environmentally sustainable evolution ... culmination of years of experience and feedback from the original version we launched ...
(Date:9/30/2019)... N.C. (PRWEB) , ... September 30, 2019 , ... As ... and an accepted model for studying the development and diseases of the human heart, ... potential activities of the progeny heart muscle cells to be clearly and easily recorded. ...
(Date:9/25/2019)... (PRWEB) , ... September 25, 2019 , ... ... biopharma leaders through off-the-record collaboration and dialogue, today announces its inaugural South ... Orleans BioInnovation Center in Louisiana. , Co-produced by Tulane University, this invitation-only ...
Breaking Biology News(10 mins):